Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Proteomics. 2018 Apr;18(7):e1700417. doi: 10.1002/pmic.201700417

Figure 2.

Figure 2.

Pharmacoproteomics strategy for acamprosate treatment using label-free proteomics. A. Pharmacoproteomics workflow for NAc of ENT1 +/+ mice and in ENT1 –/– mice. Brain coordinates for NAc tissue collection. B. Label-free proteomics approach to identify acamprosate efficacy mechanism. Accumbal proteins were separated using SDS PAGE (n = 4 per group). C. Pharmacoproteomics analysis in the NAc of ENT1−/− mice in response to acamprosate treatment. (a) 181 proteins were changed in response to both genotype and acamprosate treatment. Among 181 proteins, 50 proteins were changes in both genotypes. (b) 130 proteins were changed by genotype only. (c) 729 proteins were changed by acamprosate treatment only. Among 729 proteins, 83 proteins were changes in both genotypes. (d) 2594 proteins were not changed by either genotype or treatment.